Search results
Showing 421 to 435 of 1455 results for do not do recommendations
This quality standard covers care and support for adults with cerebral palsy (aged 25 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS191Show all sections
Physical activity: encouraging activity in the community (QS183)
This quality standard covers how local strategy, policy and planning and improvements to the built or natural physical environment such as public open spaces, workplaces and schools can encourage and support people of all ages and all abilities to be physically active and move more. It describes high-quality care in priority areas for improvement.
View quality statements for QS183Show all sections
Interventional procedures programme manual
Padeliporfin for untreated localised prostate cancer (TA546)
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.
Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older.
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.
Anaphylaxis: assessment and referral after emergency treatment (CG134)
This guideline covers assessment and referral for anaphylaxis. It aims to improve the quality of care for people with suspected anaphylaxis by detailing the assessments that are needed and recommending referral to specialist allergy services.
Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults.
Pharmalgen for the treatment of bee and wasp venom allergy (TA246)
Evidence-based recommendations on bee venom and wasp venom (Pharmalgen) for treating bee and wasp venom allergy.
Physical activity: brief advice for adults in primary care (PH44)
This guideline covers providing brief advice on physical activity to adults in primary care. It aims to improve health and wellbeing by raising awareness of the importance of physical activity and encouraging people to increase or maintain their activity level.
Cardiovascular disease: identifying and supporting people most at risk of dying early (PH15)
This guideline covers the risk of early death from heart disease and other smoking-related illnesses. It aims to reduce the number of people who are disadvantaged dying prematurely by ensuring people have better access to flexible, well-coordinated treatment and support.
Heart valve disease presenting in adults: investigation and management (NG208)
This guideline covers investigation and management of heart valve disease presenting in adults. It aims to improve quality of life and survival for people with heart valve disease through timely diagnosis and appropriate intervention.
This quality standard covers the care of people with breast cancer after they have been referred to a specialist team. It includes the management of early (ductal carcinoma in situ and invasive), locally advanced and advanced breast cancer; recurrent breast cancer; and familial breast cancer. It describes high-quality care in priority areas for improvement.
View quality statements for QS12Show all sections
Sections for QS12
- Quality statements
- Quality statement 1: Timely diagnosis
- Quality statement 2: Preoperative MRI scan
- Quality statement 3: Tumour profiling tests
- Quality statement 4: ER and HER2 receptor status
- Quality statement 5: Multidisciplinary team management of metastatic breast cancer
- Quality statement 6: Key worker
- Update information
Depression in children and young people: identification and management (NG134)
This guideline covers identifying and managing depression in children and young people aged 5 to 18 years. Based on the stepped-care model, it aims to improve recognition and assessment and promote effective treatments for mild and moderate to severe depression.
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.